

N-[¹⁸F]Fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline

[¹⁸F]PBR06

Kam Leung, PhD¹

Created: June 6, 2007; Updated: March 11, 2010.

Chemical name:	N-[¹⁸ F]Fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline	
Abbreviated name:	[¹⁸ F]PBR06	
Synonym:		
Agent category:	Compound	
Target:	Peripheral-type benzodiazepine receptor (PBR), also known as translocator protein (TSPO)	
Target category:	Receptor	
Method of detection:	PET	
Source of signal:	¹⁸ F	
Activation:	No	
Studies:	<ul style="list-style-type: none">• <i>In vitro</i>• Non-human primates• Humans	

Click on the above structure for additional information in [PubChem](#).

¹ National Center for Biotechnology Information, NLM, NIH; Email: micad@ncbi.nlm.gov.

☒ Corresponding author.

Background

[PubMed]

Benzodiazepines are potent psychoactive drugs used for their sedative and anxiolytic properties (1, 2). There are two types of benzodiazepine receptors, which have been designated as central benzodiazepine receptors (CBR) and peripheral benzodiazepine receptors (PBR). PBR is also known as translocator protein (TSPO). The CBR is found exclusively in the central nervous system on the membranes of neurons and is coupled to the γ -aminobutyric acid receptor/chloride channel (3). In contrast, the PBR is a mitochondrial protein found in brain and peripheral tissues (adrenal gland, heart, lung, kidney, and testis) (4). The brain has lower levels of PBR than do the peripheral tissues. Both glial cells and macrophages contain high levels of PBR (5-7). Increased PBR expression after brain injury or neuroinflammation is associated with microglial activation, such as occurs with the neuronal damage that accompanies several neurodegenerative diseases, including Alzheimer's disease, Wernicke's encephalopathy, multiple sclerosis, and epilepsy.

PBRs have been studied *in vivo* by positron emission tomography (PET) using 1-(2-chlorophenyl)-*N*-[^{11}C]methyl-*N*-(1-methylpropyl)-3-isoquinoline carboxamide ([^{11}C]PK11195), an isoquinoline carboxamide with specific PBR antagonistic activity (8). [^{11}C]PK11195 has been developed as a PET agent for non-invasive studies of microglia and macrophage activation in the brain, lung, and heart. However, accumulation of this tracer in the brain is limited. *N*-(2,5-Dimethoxybenzyl)-*N*-(5-fluoro-2-phenoxyphenyl)acetamide (DAA1106) was found to be a selective agonist for studying PBRs in the central nervous system (9, 10). DAA1106 was reported to have a higher affinity for PBRs in mitochondrial fractions of rat and monkey brains than PK11195 (9, 10). Therefore, both tracers are able to cross the normal cell membrane to reach the mitochondrial receptor sites. *N*-(5-Fluoro-2-phenoxyphenyl)-*N*-(2-[^{18}F]fluoroethyl-5-methoxybenzyl)acetamide ([^{18}F]FEDAA1106) and [^{11}C]DAA1106 have been developed as potential PET ligands with highly selective and specific binding to PBR (11, 12). *N*-[^{18}F]Fluoroacetyl-*N*-(2,5-dimethoxybenzyl)-2-phenoxyaniline ([^{18}F]PBR06), which has an aryloxyanilide structure, has been evaluated for imaging PBR in the brain.

Related Resource Links:

- [Chapters in MICAD](#)
- [Gene information in NCBI \(PBR\)](#)
- [Articles in OMIM](#)
- [Clinical trials \(PBR\)](#)

Synthesis

[PubMed]

Imaizumi et al. (13) reported the synthesis of [¹⁸F]PBR06 by nucleophilic displacement of the bromo precursor with [¹⁸F]KF/Kryptofix 2.2.2./K₂CO₃ at 110°C for 10 min and purified by high-performance liquid chromatography. The specific activity was 26.8 ± 17.5 GBq/μmol (0.72 ± 0.47 Ci/μmol) at the time of injection with 10–20% radiochemical yield.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

In vitro [³H]PK11195 PBR-binding studies using monkey brain mitochondrial homogenates showed inhibition constant (*K_i*) values of 0.30 ± 0.08 nM and 3.84 ± 1.26 nM for PBR06 and PK11195, respectively.

Animal Studies

Rodents

[PubMed]

No publications are currently available.

Other Non-Primate Mammals

[PubMed]

No publications are currently available.

Non-Human Primates

[PubMed]

Imaizumi et al. (13) reported PET studies of [¹⁸F]PBR06 in the monkey brain. The radioactivity level of [¹⁸F]PBR06 in the monkey brain was 300% of the standard uptake value with greater radioactivity in gray matter than in white matter. [¹⁸F]PBR06 exhibited the highest uptake in the choroid plexus, a region rich in PBR. Accumulation of [¹⁸F]PBR06 in the cerebellum, putamen, and choroid plexus was inhibited significantly (~80%) by pretreatment of DAA1106 (3 mg/kg), indicating that the binding of [¹⁸F]PBR06 in the monkey brain was mainly attributable to PBR. Averaged distribution volume (*V_T*) values by a two-tissue compartment model were 60, 80, and 78 ml/cm³ in the cerebellum, putamen, and choroid plexus, respectively. *V_T* values by a one-tissue compartment model were 49, 65, and 49 ml/cm³ in the cerebellum, putamen, and choroid plexus, respectively. In the blocking experiment, *V_T* values by a one-tissue compartment model were 2.0, 2.4, and 2.3 ml/cm³ in the cerebellum, putamen, and choroid plexus, respectively. Therefore, ~95% of *V_T* in the baseline scans was PBR-specific binding. The *V_T* value was more stable and more reliably determined with 200 min of baseline scanning using the two-compartment model than the one-compartment model.

Approximately 20–30% of radioactivity in the plasma was intact [^{18}F]PBR06 at 5 min after injection. The metabolites were more hydrophilic than the parent compound.

Human Studies

[PubMed]

Fujimura et al. (14) performed PET kinetics studies of the brain for 5 h after injection of 185 MBq (5 mCi) of [^{18}F]PBR06 in 9 healthy subjects. A 2-tissue compartment model was shown to be better than a 1-tissue compartment model. A brain scan of 120 min exhibited the best estimation of V_T value, which was stable during 60-120 min.

Fujimura et al. (15) later performed 2-dimensional dynamic scans for radiation dosimetry after injection of 185 MBq (5 mCi) of [^{18}F]PBR06 in 7 healthy subjects. The highest radiation doses were in the gallbladder wall (367.0 $\mu\text{Sv}/\text{MBq}$, 1380 mrem/mCi), spleen (64.5 $\mu\text{Sv}/\text{MBq}$, 239 mrem/mCi), liver (46.1 $\mu\text{Sv}/\text{MBq}$, 170 mrem/mCi), kidneys (39.3 $\mu\text{Sv}/\text{MBq}$, 146 mrem/mCi), lung (36.5 $\mu\text{Sv}/\text{MBq}$, 135 mrem/mCi), and urinary bladder wall (31.0 $\mu\text{Sv}/\text{MBq}$, 115 mrem/mCi). The effective dose was 18.5 $\mu\text{Sv}/\text{MBq}$ (69 mrem/mCi).

NIH Support

Intramural research program

References

1. Mohler H., Okada T. *Benzodiazepine receptor: demonstration in the central nervous system*. Science. 1977;198(4319):849–51. PubMed PMID: 918669.
2. Hunkeler W., Mohler H., Pieri L., Polc P., Bonetti E.P., Cumin R., Schaffner R., Haefely W. *Selective antagonists of benzodiazepines*. Nature. 1981;290(5806):514–6. PubMed PMID: 6261143.
3. Olsen R.W., Tobin A.J. *Molecular biology of GABAA receptors*. FASEB J. 1990;4(5):1469–80. PubMed PMID: 2155149.
4. Anholt R.R., Pedersen P.L., De Souza E.B., Snyder S.H. *The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane*. J Biol Chem. 1986;261(2):576–83. PubMed PMID: 3001071.
5. Jones H.A., Valind S.O., Clark I.C., Bolden G.E., Krausz T., Schofield J.B., Boobis A.R., Haslett C. *Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits*. Toxicol Appl Pharmacol. 2002;183(1):46–54. PubMed PMID: 12217641.
6. Kuhlmann A.C., Guilarte T.R. *Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity*. J Neurochem. 2000;74(4):1694–704. PubMed PMID: 10737628.
7. Zavala F., Lenfant M. *Benzodiazepines and PK 11195 exert immunomodulating activities by binding on a specific receptor on macrophages*. Ann N Y Acad Sci. 1987;496:240–9. PubMed PMID: 2886095.

8. Gerhard A., Neumaier B., Elitok E., Glatting G., Ries V., Tomczak R., Ludolph A.C., Reske S.N. *In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke*. Neuroreport. 2000;11(13):2957–60. PubMed PMID: 11006973.
9. Okuyama S., Chaki S., Yoshikawa R., Ogawa S., Suzuki Y., Okubo T., Nakazato A., Nagamine M., Tomisawa K. *Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106*. Life Sci. 1999;64(16): 1455–64. PubMed PMID: 10321725.
10. Chaki S., Funakoshi T., Yoshikawa R., Okuyama S., Okubo T., Nakazato A., Nagamine M., Tomisawa K. *Binding characteristics of [3H]DAA1106, a novel and selective ligand for peripheral benzodiazepine receptors*. Eur J Pharmacol. 1999;371(2-3):197–204. PubMed PMID: 10357257.
11. Fujimura Y., Ikoma Y., Yasuno F., Suhara T., Ota M., Matsumoto R., Nozaki S., Takano A., Kosaka J., Zhang M.R., Nakao R., Suzuki K., Kato N., Ito H. *Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain*. J Nucl Med. 2006;47(1):43–50. PubMed PMID: 16391186.
12. Maeda J., Suhara T., Zhang M.R., Okauchi T., Yasuno F., Ikoma Y., Inaji M., Nagai Y., Takano A., Obayashi S., Suzuki K. *Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain*. Synapse. 2004;52(4):283–91. PubMed PMID: 15103694.
13. Imaizumi M., Briard E., Zoghbi S.S., Gourley J.P., Hong J., Musachio J.L., Gladding R., Pike V.W., Innis R.B., Fujita M. *Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain*. Synapse. 2007;61(8): 595–605. PubMed PMID: 17455247.
14. Fujimura Y., Zoghbi S.S., Simeon F.G., Taku A., Pike V.W., Innis R.B., Fujita M. *Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, (18)F-PBR06*. J Nucl Med. 2009;50(7):1047–53. PubMed PMID: 19525468.
15. Fujimura Y., Kimura Y., Simeon F.G., Dickstein L.P., Pike V.W., Innis R.B., Fujita M. *Biodistribution and radiation dosimetry in humans of a new PET ligand, (18)F-PBR06, to image translocator protein (18 kDa)*. J Nucl Med. 2010;51(1):145–9. PubMed PMID: 20008980.